INCB160058 (novel investigational agent for MPN)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-04-06 — A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms: Early-phase clinical trial (Phase 1/1b) underway evaluating safety, tolerability, and pharmacokinetics of INCB160058 in MPN patients; mechanism not disclosed in abstract. (novelty: 3)
Open questions
Related
Contributing findings
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
06-apr-2026
novelty 3
per-area 3
introduces